Skip to content
Home/Companies/Industry / Biotech/Synthace
Synthace

Synthace

Industry / Biotech·UK·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Synthace?

Synthace is currently owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage), since 2019.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC

Key facts

HQUnited Kingdom
SectorIndustry / Biotech
Websitewww.synthace.com

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
GenSight Biologics
Active
BiotechFrance
Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUK· 2021
to
Artios Pharma
Artios Pharma
Active
BiotechUK· 2020
Calliditas
Calliditas
Exited 2024
BiotechSweden· 2020
to
Hemab Therapeutics
Hemab Therapeutics
Active
BiotechDenmark· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Synthace

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Synthace?

2 strategic and 118financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Synthace.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue